Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

European Journal of Cancer

Volumn 38, Issue 8, 2002, Pages 1133-1140

  Jung, Y D ^a   Mansfield, P F ^a   Akagi, M ^a   Takeda, A ^a   Liu, W ^a   Bucana, C D ^a   Hicklin, D J ^a,b   Ellis, L M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; EGF; Gastric cancer; Growth factors; VEGF

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STOMACH CARCINOMA; STOMACH WALL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036252329     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00013-8     Document Type: Article

References (28)

1. Gastritis and gastric cancer. Asia
2. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer
3. Angiogenesis in cancer, vascular, rhuematoid and other disease
4. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
5. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
6. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma
7. Growth factors in progression of human esophageal and gastric carcinomas
8. Epidermal growth factor-receptor expression correlates with tumor cell proliferation and prognosis in gastric cancer
9. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
10. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
11. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
12. Epidermal growth factor induces the expression of its receptor gene in human gastric carcinoma cell line TMK-1
13. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
14. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer
15. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms
16. Efficacy results of a phase I/II study of SU5416 (S)/5-fluorouracil (F)/leuocovorin (L) relative to results in random subsets of similar patients (Pts) from a phase III study fo Irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC)
17. Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody
18. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
19. Tissue status of epidermal growth factor and its receptor as an indicator of poor prognosis in patients with gastric cancer
20. Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer
21. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells
22. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells
23. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
24. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide
25. Jeremiah Metzger Lecture. Targeted cancer therapy
26. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
27. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells
28. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells